ダウンロード数: 1238

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s00280-013-2151-8.pdf450.42 kBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorKanai, Masashien
dc.contributor.authorOtsuka, Yoshihikoen
dc.contributor.authorOtsuka, Kazunorien
dc.contributor.authorSato, Maremien
dc.contributor.authorNishimura, Takafumien
dc.contributor.authorMori, Yukikoen
dc.contributor.authorKawaguchi, Michiyaen
dc.contributor.authorHatano, Etsuroen
dc.contributor.authorKodama, Yuzoen
dc.contributor.authorMatsumoto, Shigemien
dc.contributor.authorMurakami, Yoshikien
dc.contributor.authorImaizumi, Atsushien
dc.contributor.authorChiba, Tsutomuen
dc.contributor.authorNishihira, Junen
dc.contributor.authorShibata, Hiroyukien
dc.contributor.alternative金井, 雅史ja
dc.date.accessioned2014-09-30T00:16:51Z-
dc.date.available2014-09-30T00:16:51Z-
dc.date.issued2013-06-
dc.identifier.issn0344-5704-
dc.identifier.urihttp://hdl.handle.net/2433/189888-
dc.description.abstractA growing number of preclinical studies have demonstrated that curcumin could be a promising anticancer drug; however, poor bioavailability has been the major obstacle for its clinical application. To overcome this problem, we developed a new form of curcumin (Theracurmin) and reported high plasma curcumin levels could be safely achieved after a single administration of Theracurmin in healthy volunteers. In this study, we aimed to evaluate the safety of repetitive administration of Theracurmin in cancer patients.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer-Verlagen
dc.rightsThe final publication is available at Springer via http://dx.doi.org/10.1007/s00280-013-2151-8en
dc.rightsこの論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。ja
dc.rightsThis is not the published version. Please cite only the published version.en
dc.subjectCurcuminen
dc.subjectBioavailabilityen
dc.subjectTheracurmin®en
dc.subjectGemcitabineen
dc.subjectPancreatic canceren
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols/administration & dosageen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols/adverse effectsen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols/chemistryen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols/pharmacokineticsen
dc.subject.meshBiliary Tract Neoplasms/drug therapyen
dc.subject.meshBiliary Tract Neoplasms/metabolismen
dc.subject.meshBiliary Tract Neoplasms/mortalityen
dc.subject.meshBiological Availabilityen
dc.subject.meshCurcumin/administration & dosageen
dc.subject.meshCurcumin/adverse effectsen
dc.subject.meshCurcumin/chemistryen
dc.subject.meshCurcumin/pharmacokineticsen
dc.subject.meshCytokines/antagonists & inhibitorsen
dc.subject.meshCytokines/immunologyen
dc.subject.meshDisease-Free Survivalen
dc.subject.meshDose-Response Relationship, Drugen
dc.subject.meshDrug Administration Scheduleen
dc.subject.meshDrug Compoundingen
dc.subject.meshDrug Stabilityen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMaximum Tolerated Doseen
dc.subject.meshMiddle Ageden
dc.subject.meshNF-kappa B/antagonists & inhibitorsen
dc.subject.meshPancreatic Neoplasms/drug therapyen
dc.subject.meshPancreatic Neoplasms/metabolismen
dc.subject.meshPancreatic Neoplasms/mortalityen
dc.subject.meshQuality of Lifeen
dc.subject.meshSolubilityen
dc.titleA phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.en
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.ncidAA00598397-
dc.identifier.jtitleCancer chemotherapy and pharmacologyen
dc.identifier.volume71-
dc.identifier.issue6-
dc.identifier.spage1521-
dc.identifier.epage1530-
dc.relation.doi10.1007/s00280-013-2151-8-
dc.textversionauthor-
dc.identifier.pmid23543271-
dcterms.accessRightsopen access-
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。